可溶性晚期糖基化终产物受体与内源性分泌型可溶性晚期糖基化终产物受体水平与糖尿病颈动脉粥样硬化的关系：系统评价和荟萃分析。

Association Between Soluble Receptor for Advanced Glycation End Product and Endogenous Secretory Soluble Receptor for Advanced Glycation End Product Levels and Carotid Atherosclerosis in Diabetes: A Systematic Review and Meta-Analysis.

机构信息

Department of Neurosurgery, Weinan Central Hospital, Weinan, Shaanxi Province, People's Republic of China.

Department of Ultrasound Diagnosis, Weinan Maternal and Child Health Hospital, Weinan, Shaanxi Province, People's Republic of China.

出版信息

Can J Diabetes. 2021 Oct;45(7):634-640. doi: 10.1016/j.jcjd.2021.01.004. Epub 2021 Jan 20.

DOI:10.1016/j.jcjd.2021.01.004

PMID:33773934

Abstract

BACKGROUND

The soluble receptor for advanced glycation end product (sRAGE) and endogenous secretory RAGE (esRAGE) are novel biomarkers that are associated with vascular disease. We carried out a systematic review to provide a more complete picture of sRAGE, esRAGE, carotid atherosclerosis and cardiovascular disease (CVD) in patients with diabetes.

METHODS

We searched the Cochrane Library, PubMed and Embase databases. Systematic review best practices were followed, and study quality was assessed.

RESULTS

Ultimately, 11 studies met all the inclusion criteria. Meta-analysis indicated that esRAGE was not significantly lower in patients with type 1 diabetes (T1D) (standardized mean difference [SMD], -0.76; 95% confidence interval [CI], -1.57 to 0.05; I=90%; p=0.002), whereas it was significantly lower in patients with type 2 diabetes (T2D) (SMD, -1.08; 95% CI, -1.53 to -0.62; I=80%; p=0.006). Meta-analysis suggested that sRAGE levels were not significantly lower or higher in T1D (SMD, 0.06; 95% CI, -0.14 to 0.26; I=38%; p=0.20) or T2D (SMD, 0.00; 95% CI, -0.26 to 0.26; I=0.00%; p=1.00) patients. The level of esRAGE was inversely correlated with carotid intima-media thickness (IMT) in T2D patients, whereas there was a contrasting relationship between sRAGE and carotid IMT in T1D patients. Higher sRAGE was associated with cardiovascular events.

CONCLUSION

Our meta-analysis showed that circulating esRAGE was lower and inversely correlated with IMT in T2D patients.

摘要

背景

晚期糖基化终产物可溶性受体（sRAGE）和内源性分泌型 RAGE（esRAGE）是与血管疾病相关的新型生物标志物。我们进行了一项系统评价，以更全面地了解糖尿病患者的 sRAGE、esRAGE、颈动脉粥样硬化和心血管疾病（CVD）。

方法

我们检索了 Cochrane 图书馆、PubMed 和 Embase 数据库。遵循系统评价最佳实践，并评估研究质量。

结果

最终，有 11 项研究符合所有纳入标准。荟萃分析表明，1 型糖尿病（T1D）患者的 esRAGE 水平没有显著降低（标准化均数差 [SMD]，-0.76；95%置信区间 [CI]，-1.57 至 0.05；I=90%；p=0.002），而 2 型糖尿病（T2D）患者的 esRAGE 水平显著降低（SMD，-1.08；95%CI，-1.53 至-0.62；I=80%；p=0.006）。荟萃分析表明，T1D（SMD，0.06；95%CI，-0.14 至 0.26；I=38%；p=0.20）或 T2D（SMD，0.00；95%CI，-0.26 至 0.26；I=0.00%；p=1.00）患者的 sRAGE 水平没有显著降低或升高。T2D 患者的 esRAGE 水平与颈动脉内膜-中层厚度（IMT）呈负相关，而 T1D 患者的 sRAGE 与颈动脉 IMT 呈相反关系。较高的 sRAGE 与心血管事件相关。